Capricor Therapeutics, Inc.
NASDAQ:CAPRBiotechnology
-$0.14 today
- Market cap
- $487.04M
- Beta
- 0.37
- P/E (TTM)
- -13.9
- EPS (TTM)
- -$2.00
Volume 4.62M
Average 1.08M
Returns on capital
Capricor Therapeutics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-34.4%
avg 70.7%
ROIC
-33.4%
avg -87.7%
ROA
-29.5%
avg -57.8%
Analysis
ROA is currently the strongest return metric at -29.5% versus its period average of -57.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Anthony J. Bergmann | Chief Financial Officer & Corporate Treasurer | USD 584.75K | 40 | — | — |
Linda Marbán | Co-Founder, President, Chief Executive Officer & Director | USD 580.65K | 63 | 7.50K | 0.02% |
Karen G. Krasney | Executive Vice President, General Counsel & Secretary | USD 500.72K | 73 | — | — |
Frank Isaac Litvack FACC | Executive Chairman of the Board | USD 120K | 70 | — | — |
Kristi A. H. Elliott | Chief Operating & Science Officer | — | — | — | — |
Mark Awadalla | Chief Development Officer | — | — | — | — |
Michael Maurer | Chief Commercial Officer | — | — | — | — |
Minghao Sun | Senior Vice President of Quality Control, Research & Product Development | — | — | — | — |
Nathaniel Hogan | Director of Biostatistics of Capricor Therapeutics | — | — | — | — |
Micheal Binks | Chief Medical Officer | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jan 5, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
11
$8.34M
Net Transaction Value
−$8.34M
Net selling
Most Active
Bergmann Anthony
4 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Jun 25, 26Jun 25, 2026 | Bergmann Anthony Direct | Sell | $732.2K$732,158.00 |
| Jun 25, 26Jun 25, 2026 | Krasney Karen Direct | Sell | $732.2K$732,158.00 |
| Jun 24, 26Jun 24, 2026 | Bergmann Anthony Direct | Sell | $12K$12,000.00 |
| Jun 24, 26Jun 24, 2026 | Krasney Karen Direct | Sell | $12K$12,000.00 |
| May 1, 26May 1, 2026 | Krasney Karen Direct | Sell | $792.5K$792,547.50 |
| May 1, 26May 1, 2026 | Bergmann Anthony Direct | Sell | $792.5K$792,540.00 |
| Apr 2, 26Apr 2, 2026 | Sabar Karimah Es Direct | Sell | $240.9K$240,928.00 |
| Apr 1, 26Apr 1, 2026 | Sabar Karimah Es Direct | Sell | $1.7M$1,667,225.10 |
| Mar 31, 26Mar 31, 2026 | Sabar Karimah Es Direct | Sell | $1.8M$1,848,242.52 |
| Mar 31, 26Mar 31, 2026 | Krasney Karen Direct | Sell | $752.9K$752,935.00 |
1–10 of 11
Summary
Insiders reported 0 buys worth $0.00 and 11 sells worth $8.34M over the last 12 months. That adds up to net selling of $8.34M. Bergmann Anthony was the most active insider with 4 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Capricor Therapeutics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about CAPR's management, answered from reported figures.
Who manages CAPR?
Capricor Therapeutics, Inc. (CAPR) lists 10 active executives. The top listed executive is Frank Isaac Litvack FACC, Executive Chairman of the Board.
Are CAPR insiders buying or selling?
Recent insider activity shows net selling of $916.36M.
Continue the stock analysis
Jump to another research area for this company.